pSivida drug delivery data
This article was originally published in The Gray Sheet
Executive Summary
Preliminary data from a four-patient safety trial suggest that pSivida's BrachySil nanotechnology liver cancer treatment device achieves 80% tumor regression by volume, with no product-related adverse events. A dose-profiling study will begin shortly, followed by a multicenter pivotal trial in Europe and the U.S. The Australian firm aims to license the drug-delivery device to a top pharma firm during 2005 (1"The Gray Sheet" Feb. 14, 2005, p. 28)...
You may also be interested in...
Silicon-Based Nanotech Drug-Delivery Firm Developing Brachytherapy Device
pSivida will launch a brachytherapy delivery device in 2007 outside the U.S. to demonstrate the capabilities of its nanotechnology drug-delivery platform to potential pharmaceutical partners
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.